PIK3CA and neoplasm: Higgins et al. [17] demonstrated a 100% concordance between using BEAMing to assess PIK3CA mutations in plasma cfDNA versus using BEAMing for PIK3CA mutations in the tumor tissue in a cohort of patients with advanced breast cancer when the plasma and tumor samples were obtained at the same time.